A trial assessing Coronavirus vaccine
Latest Information Update: 18 Jan 2021
At a glance
- Drugs GEO CM1 (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
Most Recent Events
- 11 Jan 2021 According to a Geovax media release, National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded the Company a Small Business Innovative Research (SBIR) grant in support of its development of a vaccine against SARS-CoV-2, the virus that causes COVID-19
- 20 Mar 2020 New trial record
- 18 Mar 2020 According to a Geovax media release, this trial is expected to start before the end of this year.
Trial Overview
Purpose
This trial will be assessing the coronavirus vaccine.
Diseases Treated
Indication | Qualifiers | Patient Segments |
---|---|---|
COVID 2019 infections | treatment | - |
Subjects
- Subject Type patients
- Sex male & female
- Age Group adult
Trial Details
Organisations
- Affiliations GeoVax Labs
Trial Dates
Other Details
- Design prospective
- Phase of Trial Phase I
- Location Unknown
- Focus Therapeutic Use
Interventions
Drugs | Route | Formulation | Target |
---|---|---|---|
GEO CM1 Primary Drug
|
-
|
-
|
-
|
Coronavirus-vaccine
Trial History
Event Date | Event Type | Comment |
---|---|---|
11 Jan 2021 | Other trial event | According to a Geovax media release, National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded the Company a Small Business Innovative Research (SBIR) grant in support of its development of a vaccine against SARS-CoV-2, the virus that causes COVID-19 Updated 18 Jan 2021 |
20 Mar 2020 | New trial record | New trial record Updated 20 Mar 2020 |
18 Mar 2020 | Other trial event | According to a Geovax media release, this trial is expected to start before the end of this year. Updated 20 Mar 2020 |
References
-
GeoVax Labs. GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program. Media-Rel 2020;.
Media Release -
GeoVax Labs. GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development. Media-Rel 2021;.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG